Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III ...

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

While the data presented are promising, botensilimab, balstilimab, and agenT-797 are currently investigational agents and have not been approved for therapeutic use in any jurisdiction. InvestingPro ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, ...

First-Line and FOLFOX Rechallenged MSS CRC ... objective response rate in microsatellite stable metastatic colorectal cancer, a disease where responses to immunotherapy have historically been ...